CytomX Therapeutics, Inc. License Agreements
5 Contracts & Agreements
- Amendment No.3 to Exclusive License Agreement effective as of April 2, 2019, by and between CytomX Therapeutics, Inc. and The Regents of the University of California (Filed With SEC on May 9, 2019)
- License Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of February 12,2016 (Filed With SEC on November 6, 2018)
- Third Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of January 3, 2018 (Filed With SEC on November 6, 2018)
- Second Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of March 31, 2017 (Filed With SEC on November 6, 2018)
- First Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of October 5, 2016 (Filed With SEC on November 6, 2018)
